Omega 3 fatty acids increase the chemo-sensitivity of B-CLL-derived cell lines EHEB and MEC-2 and of B-PLL-derived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine and fludarabine

Lipids in Health and Disease

Volumn 12, Issue 1, 2013, Pages

  Fahrmann, Johannes F ^a   Hardman, W Elaine ^a  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemo sensitization; Chronic lymphocytic leukemia; Omega 3

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; DOXORUBICIN; FLUDARABINE; ICOSAPENTAENOIC ACID; LIPID PEROXIDE; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL DEATH; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID COMPOSITION; LIPID PEROXIDATION; MONOTHERAPY; PROLYMPHOCYTIC LEUKEMIA;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARACHIDONIC ACID; CELL LINE, TUMOR; DOCOSAHEXAENOIC ACIDS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EICOSAPENTAENOIC ACID; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, PROLYMPHOCYTIC, B-CELL; LIPID PEROXIDATION; MALONDIALDEHYDE; ORGAN SPECIFICITY; REACTIVE OXYGEN SPECIES; VIDARABINE; VINCRISTINE; VITAMIN E;

EID: 84874930167     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-12-36     Document Type: Article

References (29)

1. Chronic lymphocytic leukemia: an update on biology and treatment. Riches JC, Ramsay AG, Gribben JG, Curr Oncol Rep 2011 13 379 385 10.1007/s11912-011- 0188-6 21773694
2. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Silber R, Degar B, Costin D, Newcomb EW, Mani M, Blood 1994 84 3440 3446 7949099
3. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia. Schriever F, Huhn D, Drugs 2003 63 953 969 10.2165/00003495- 200363100-00003 12699399
4. Omega-3 fatty acids in health and disease and in growth and development. Simopoulos AP, Am J Clin Nutr 1991 54 438 463 1908631
5. Human requirement for N-3 polyunsaturated fatty acids. Simopoulos AP, Poult Sci 2000 79 961 970 10901194
6. The importance of the ratio of omega-6/omega-3 essential fatty acids. Simopoulos AP, Biomed Pharmacother 2002 56 365 379 10.1016/S0753-3322(02)00253-6 12442909
7. Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation. Germain E, Chajes V, Cognault S, Lhuillery C, Bougnoux P, Int J Cancer 1998 75 578 583 10.1002/(SICI)1097-0215(19980209)75:4<578::AID- IJC14>3.0.CO;2-5 9466659
8. Effects of polyunsaturated fatty acids on the efficacy of antineoplastic agents toward L5178Y lymphoma cells. Kinsella JE, Black JM, Biochem Pharmacol 1993 45 1881 1887 10.1016/0006-2952(93)90447-5 8494547
9. Effects of dietary fish oil on human mammary carcinoma and on lipid-metabolizing enzymes. Borgeson CE, Pardini L, Pardini RS, Reitz RC, Lipids 1989 24 290 295 10.1007/BF02535165 2502698
10. Intervention of transplantable human mammary carcinoma MX-1 chemotherapy with dietary menhaden oil in athymic mice: increased therapeutic effects and decreased toxicity of cyclophosphamide. Shao Y, Pardini L, Pardini RS, Nutr Cancer 1997 28 63 73 10.1080/01635589709514554 9200152
11. Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts. Hardman WE, Avula CP, Fernandes G, Cameron IL, Clin Cancer Res 2001 7 2041 2049 11448922
12. Inhibition of Nuclear Factor Kappa B activation in Early-Stage Chronic Lymphocytic Leukemia by Omega-3 Fatty Acids. Fahrmann JF, Ballester OF, Ballester G, Witte TR, Salazar AJ, Cancer Invest 2013 31 29 43
13. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Muller C, Chatelut E, Gualano V, De Forni M, Huguet F, Cancer Chemother Pharmacol 1993 32 379 384 10.1007/BF00735923 8339389
14. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. Foran JM, Oscier D, Orchard J, Johnson SA, Tighe M, J Clin Oncol 1999 17 1574 1579 10334546
15. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Guilhaumou R, Solas C, Bourgarel-Rey V, Quaranta S, Rome A, Cancer Chemother Pharmacol 2011 68 1633 1638 10.1007/s00280-011-1745-2 21968951
16. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Blood 2001 98 2319 2325 10.1182/blood.V98.8.2319 11588025
17. A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Van der Jagt R, Laneuville P, Macdonald D, Stewart D, Christofides A, Curr Oncol 2012 19 160 168 22670095
18. Molecular pathogenesis of chronic lymphocytic leukemia. Gaidano G, Foa R, Dalla-Favera R, J Clin Invest 2012 122 3432 3438 10.1172/JCI64101 23023714
19. G2/M cell-cycle arrest and apoptosis by n-3 fatty acids in a pancreatic cancer model. Dekoj T, Lee S, Desai S, Trevino J, Babcock TA, J Surg Res 2007 139 106 112 10.1016/j.jss.2006.10.024 17291531
20. Microtubule interfering agents and KSP inhibitors induce the phosphorylation of the nuclear protein p54(nrb), an event linked to G2/M arrest. Casado P, Prado MA, Zuazua-Villar P, Del Valle E, Artime N, J Proteomics 2009 71 592 600 10.1016/j.jprot.2008.09.001 18832053
21. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Ling YH, el-Naggar AK, Priebe W, Perez-Soler R, Mol Pharmacol 1996 49 832 841 8622633
22. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R, Clin Cancer Res 2002 8 3512 3519 12429642
23. Xanthatin induces cell cycle arrest at G2/M checkpoint and apoptosis via disrupting NF-kappaB pathway in A549 non-small-cell lung cancer cells. Zhang L, Ruan J, Yan L, Li W, Wu Y, Molecules 2012 17 3736 3750 10.3390/molecules17043736 22450683
24. Xanthatin induces G2/M cell cycle arrest and apoptosis in human gastric carcinoma MKN-45 cells. Zhang L, Tao L, Ruan J, Li W, Wu Y, Planta Med 2012 78 890 895 22532019
25. Docosahexaenoic acid induces apoptosis in MCF-7 cells in vitro and in vivo via reactive oxygen species formation and caspase 8 activation. Kang KS, Wang P, Yamabe N, Fukui M, Jay T, PLoS One 2010 5 10296 10.1371/journal.pone. 0010296 20421971
26. Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. Begin ME, Ells G, Das UN, Horrobin DF, J Natl Cancer Inst 1986 77 1053 1062 3464797
27. Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. Begin ME, Ells G, Horrobin DF, J Natl Cancer Inst 1988 80 188 194 10.1093/jnci/80.3.188 3346910
28. Effect of polyunsaturated fatty acids on drug-sensitive and resistant tumor cells in vitro. Das UN, Madhavi N, Lipids Health Dis 2011 10 159 10.1186/1476-511X-10-159 21917129
29. RBC and WBC fatty acid composition following consumption of an omega 3 supplement: lessons for future clinical trials. Witte TR, Salazar AJ, Ballester OF, Hardman WE, Lipids Health Dis 2010 9 31 10.1186/1476-511X-9-31 20307284